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o r i g i n a l a r t i c l e
Which Comorbid Conditions Should We Be Analyzing as Risk
Factors for Healthcare-Associated Infections?
Anthony D. Harris, MD MPH;1 Lisa Pineles, MA;1 Deverick Anderson, MD, MPH;2,3 Keith F. Woeltje, MD, PhD;4,11
William E. Trick, MD;5,6 Keith S. Kaye, MD, MPH;7 Deborah S. Yokoe, MD, MPH;8 Ann-Christine Nyquist, MD, MSPH;9
David P. Calfee, MD, MS;10 Surbhi Leekha, MBBS, MPH1
objective. To determine which comorbid conditions are considered causally related to central-line associated bloodstream infection
(CLABSI) and surgical-site infection (SSI) based on expert consensus.
design. Using the Delphi method, we administered an iterative, 2-round survey to 9 infectious disease and infection control experts from the
United States.
methods. Based on our selection of components from the Charlson and Elixhauser comorbidity indices, 35 different comorbid conditions
were rated from 1 (not at all related) to 5 (strongly related) by each expert separately for CLABSI and SSI, based on perceived relatedness to the
outcome. To assign expert consensus on causal relatedness for each comorbid condition, all 3 of the following criteria had to be met at the end of
the second round: (1) a majority (>50%) of experts rating the condition at 3 (somewhat related) or higher, (2) interquartile range (IQR)≤ 1, and
(3) standard deviation (SD)≤ 1.
results. From round 1 to round 2, the IQR and SD, respectively, decreased for ratings of 21 of 35 (60%) and 33 of 35 (94%) comorbid
conditions for CLABSI, and for 17 of 35 (49%) and 32 of 35 (91%) comorbid conditions for SSI, suggesting improvement in consensus among
this group of experts. At the end of round 2, 13 of 35 (37%) and 17 of 35 (49%) comorbid conditions were perceived as causally related to
CLABSI and SSI, respectively.
conclusions. Our results have produced a list of comorbid conditions that should be analyzed as risk factors for and further explored for
risk adjustment of CLABSI and SSI.
Infect Control Hosp Epidemiol 2017;38:449–454
Comorbid conditions are associated with increased risk for
surgical site infection (SSI)1–4 and the acquisition of antibiotic-
resistant bacteria.5–7 More limited research has been done to
assess whether patients with certain comorbid conditions may be
at greater risk for central-line–associated bloodstream infections
(CLABSIs) than other patients.8,9 Research using comorbidity for
risk adjustment of healthcare-associated infection rates is in its
infancy.10 Risk adjustment based on comorbid conditions would
enhance the quality of national reporting of infection control and
infectious disease metrics, particularly as it relates to interfacility
comparisons and quality-based reimbursement by CMS.
Many risk factor studies in the infectious diseases literature
use the Charlson comorbidity index,11 which is based on the
International Classiﬁcation of Diseases (ICD). The Charlson
comorbidity index was originally developed to predict 1-year
mortality among hospitalized patients.11 This index was not
developed for infectious diseases and thus may have variables
that are not ideal for either infection control risk factor studies
or risk adjustment due to lack of biological plausibility.
The Elixhauser index is a newer comorbidity index also based
on ICD, but it also was not developed for infectious diseases.
The Elixhauser index was originally developed to predict
mortality, length of stay, and hospital charges among
inpatients.12 This index has been validated in hospital
administrative data and has a larger list of comorbid categories
than the Charlson comorbidity index.12
The Delphi technique has been used extensively to formally
build consensus among experts.13 This technique is most
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effective when there is a lack of or inadequate information
about an issue, as in the literature deﬁning comorbid
conditions as risk factors for CLABSI and SSI and their
potential use for risk adjustment. In contrast to committees
and meetings, which can be dominated by a single individual,
this technique considers all respondents’ opinions through
anonymous reporting and feedback.13 The technique is a series
of questionnaires or rounds, interspersed by controlled
feedback that aims to gain the most reliable consensus of a
group of experts.
The objective of our study was to convene a group of experts
in the ﬁelds of SSI and CLABSI and use the Delphi technique to
determine which comorbid conditions were considered related
and unrelated to these outcomes based on their knowledge of
the literature and content expertise.
methods
We selected Delphi methodology13,14 as a consensus-building
technique; it has been well-studied and is the basis for the
RAND appropriateness method.15We administered an iterative,
2-round survey broken up by a conference call (ie, survey then
conference call then survey) to 9 infectious disease and infection
control experts in the United States. Expert qualiﬁcations
included authorship on studies or guidelines related to CLABSI
and SSI (eg, SHEA compendia), leadership of institutional
healthcare epidemiology programs, and prominence in national
infectious diseases and healthcare epidemiology societies. S.L.
and A.D.H. reviewed the literature and chose the experts to
approach. We invited 10 experts, and 9 agreed to participate.
We selected 35 different comorbid condition categories
from the Charlson16 and Elixhauser12 comorbidity indices to
be considered as potential variables for risk adjustment of both
CLABSI and SSI (Table 1). These speciﬁc variables were
chosen because of their universal availability in hospital billing
and administrative databases. Using a web-based survey tool,
respondents were presented with all 35 comorbid conditions
listed in alphabetical order. Separately for SSI and CLABSI,
respondents were asked to independently rate each comorbid
condition on a Likert scale from 1 (not at all related) to
5 (strongly related), based on their perceptions of causal
relatedness with the outcome. Round 1 surveys were
completed within 3 weeks; thereafter, each respondent
received a personalized response summary showing their
rating and the number of respondents choosing other Likert
values (from 1 to 5), for all SSI and CLABSI variables.
A conference call moderated by the principal investigator was
conducted. The identical survey was repeated in a second
round after the conference call to allow respondents to modify
their ratings based on the conference-call discussion.
The following measures were calculated for each variable
under consideration, separately for CLABSI and SSI: median
and interquartile range (IQR), mean and standard deviation
(SD) (Table 1). A rating of “3” by a majority of the experts was
chosen as the causal relatedness threshold, ie, >50% of experts
would need to rate a variable at 3 or higher (3–somewhat
related, 4–related, or 5–strongly related). In addition, we
assessed expert consensus development by the change in the
interquartile range (IQR) and standard deviation (SD) of
ratings between rounds 1 and 2. A decrease in IQR and SD
indicated a decrease in the variability of the ratings and,
therefore, increase in consensus. To assign the ﬁnal expert
consensus on causal relatedness for each comorbid condition,
these 3 criteria had to be met at the end of round 2, and they
were determined prior to the call: (1) a majority (>50%) of
experts rating the condition at 3 or higher; (2) IQR≤ 1; and
(3) SD≤ 1. Thus, we incorporated both the strength of the
rating assigned to each condition and the consensus achieved
among the experts.17 Similarly, a comorbid condition was
considered causally unrelated to the outcome if in round 2 a
majority of experts rated the condition at 1, and it met the IQR
and SD criteria above. The causal relation was considered
indeterminate for the remaining comorbid conditions that
were not clearly identiﬁed as related or unrelated based on the
above criteria. Thus, the indeterminate category included
conditions for which consensus was not achieved (IQR or
SD>1 after round 2), or conditions rated “2” by most experts.
During the conference call, it was apparent that experts had
rated conditions at “2” when they were unsure of the related-
ness to the outcome, which further validated this classiﬁcation.
results
Overall, 9 experts from 8 different medical centers participated
in both surveys and the conference call. During the conference
call (lasting 2 hours), experts provided their rationale, sepa-
rately for CLABSI and SSI, for rating each comorbid condition
in round 1. More time was spent discussing ratings and
rationale for conditions in which there were clear outliers, ie,
those for which only 1–2 experts had rated the condition at
either extreme (1 or 5) or for which the ratings ranged
from 1 to 5. Examples of such variables are severe liver disease,
coagulopathy, rheumatologic disease, and congestive heart
failure, for both CLABSI and SSI. In contrast, there was less
discussion regarding items with an existing consensus and
similarity of ratings (regardless of strength of ratings) in
round 1 (eg, peptic ulcer disease and other neurologic condi-
tion). Descriptive measures of the rating for each comorbid
condition and changes in SD and IQR from round 1 to round 2
are presented in Table 1 for CLABSI and Table 2 for SSI.
Between round 1 and round 2, the IQR and SD respectively
decreased for ratings of 21 of 35 comorbid conditions (60%)
and 34 of 35 comorbid conditions (97%) for CLABSI
(Table 1); for SSI, and the IQR and SD respectively decreased
for 17 of 35 comorbid conditions (49%) and 32 of 35
comorbid conditions (91%) (Table 2). Based on our criteria
for expert consensus, at the end of round 2, 13 of 35 comorbid
conditions (37%) and 17 of 35 comorbid conditions (49%)
were perceived as causally related to CLABSI and SSI, respec-
tively (Figure 1). Moreover, 29% of comorbid conditions were
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considered not causally related to CLABSI, and 23% were
considered not causally related to SSI. The causal relatedness
was indeterminate for 34% of comorbid conditions with
CLABSI and for 28% of comorbid conditions with SSI.
discussion
Our study found that the Delphi method effectively led to the
identiﬁcation of ICD-based comorbid conditions perceived as
causally related to CLABSI and SSI by expert consensus.
Current methods used by the National Healthcare Surveil-
lance Network (NHSN) and the Centers for Disease Control and
Prevention (CDC) for CLABSI risk adjustment consist solely of
adjustment by the type of intensive care unit and aggregate
duration of central venous catheter use.18 SSI adjustment
methods are being updated continually. Prior methodology
included adjustment for the American Society of Anesthesiolo-
gists (ASA) score, the duration of surgery and whether the pro-
cedure was categorized as clean, clean contaminated, or dirty.19
The present methodology is procedure speciﬁc.20 Although it is
table 1. Descriptive Measures of and Changes Between Rounds in Expert Ratings of Perceived Causal Relatedness of Comorbid Condi-
tions with Central-Line–Associated Bloodstream Infection (N= 9)
Experts’ Likert
Ratings of 3, 4,



















in SD From Round
1 to Round 2?
Alcohol abuse 22 0 1 (1) 1 (1) N 1.67 (0.87) 1.44 (0.53) Y
Anemia (blood loss) 44 22 1 (2) 1 (0) Y 1.89 (1.05) 2.00 (0.71) Y
Anemia (deﬁciency) 0 0 1 (1) 1 (0) Y 1.44 (0.53) 1.11 (0.33) Y
Cardiac arrhythmia 0 0 1 (0) 1 (0) N 1.22 (0.44) 1.00 (0.00) Y
Cerebrovascular disease 11 0 1 (1) 1 (1) N 1.67 (0.71) 1.56 (0.53) Y
Chronic pulmonary disease 44 11 1 (2) 1 (1) Y 2.11 (0.93) 1.78 (0.67) Y
Coagulopathy 67 67 1 (1) 1 (2) N 2.78 (1.30) 3.00 (1.22) Y
Congestive heart failure 22 0 1 (1) 1 (1) N 1.89 (1.05) 1.56 (0.53) Y
Depression 0 0 1 (0) 1 (0) N 1.11 (0.33) 1.00 (0.00) Y
Dementia 33 56 1 (2) 1 (1) Y 2.00 (0.87) 2.44 (0.73) Y
Diabetes 56 56 2 (2) 2 (1) Y 3.00 (1.12) 2.78 (0.97) Y
Diabetes w/complications 56 78 2 (2) 2 (1) Y 3.33 (1.32) 3.33 (1.00) Y
Drug abuse 56 78 2 (1) 2 (0) Y 2.56 (1.13) 3.00 (0.71) Y
Fluid and electrolyte disorders 22 22 1 (1) 1 (0) Y 1.89 (0.78) 2.11 (0.60) Y
Hemiplegia or paraplegia 56 56 1 (2) 1 (1) Y 2.33 (1.12) 2.44 (0.73) Y
HIV/AIDS 67 78 1 (1) 2 (0) Y 2.78 (1.09) 2.78 (0.44) Y
Hypertension 0 0 1 (0) 1 (0) N 1.22 (0.44) 1.11 (0.33) Y
Hypertension complicated 0 0 1 (1) 1 (1) N 1.44 (0.53) 1.33 (0.50) Y
Hypothyroidism 0 0 1 (0) 1 (0) N 1.11 (0.33) 1.00 (0.00) Y
Lymphoma 78 100 2 (1) 4 (0) Y 3.44 (1.01) 4.11 (0.33) Y
Malignancy 67 100 2 (2) 3 (1) Y 3.33 (1.12) 3.67 (0.71) Y
Metastatic solid tumor 78 100 2 (1) 3 (0) Y 3.56 (1.13) 4.00 (0.50) Y
Myocardial infarction 0 0 1 (1) 1 (1) N 1.44 (0.53) 1.33 (0.50) Y
Mild liver disease 22 33 1 (1) 2 (1) N 2.00 (1.00) 2.44 (0.73) Y
Severe liver disease 67 89 1 (1) 2 (1) N 3.00 (1.32) 3.33 (0.87) Y
Neurologic (other) 11 0 1 (1) 1 (1) N 1.67 (0.71) 1.56 (0.53) Y
Obesity 44 100 2 (2) 3 (1) Y 3.11 (1.36) 3.89 (0.78) Y
Peptic ulcer 0 0 1 (0) 1 (0) N 1.11 (0.33) 1.11 (0.33) N
Peripheral vascular disease 44 44 1 (2) 1 (1) Y 2.44 (1.67) 2.67 (1.22) Y
Psychosis 0 0 1 (1) 1 (0) Y 1.44 (0.53) 1.78 (0.44) Y
Pulmonary circulation
disorders
33 22 1 (2) 1 (1) Y 1.78 (0.97) 1.78 (0.83) Y
Renal disease 56 89 1 (2) 2 (1) Y 3.00 (1.32) 3.44 (0.88) Y
Rheumatologic disease 22 0 1 (1) 2 (0) Y 2.11 (1.27) 1.89 (0.33) Y
Valvular disease 11 0 1 (1) 1 (0) Y 1.44 (0.73) 1.11 (0.33) Y
Weight loss (malnutrition) 56 89 3 (1) 3 (0) Y 2.78 (0.83) 3.11 (0.60) Y
NOTE. IQR, interquartile range; SD, standard deviation; HIV/AIDS, human immunodeﬁciency virus/acquired immune deﬁciency syndrome.
aRatings were deﬁned as follows: 1, not at all related; 2, minimally related; 3, somewhat related; 4, very related; 5, strongly related.
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better than the previous methodologies, some researchers believe
that CDCmethods of risk adjustment for CLABSI and SSI can be
further improved by including adjustment for patient-speciﬁc
comorbid conditions.10,21–23
Hospital electronic medical record capabilities are expanding.
In addition, hospital databases are becoming more readily
accessible to hospital epidemiologists, infection preventionists,
and state and government agencies. Almost all institutions in the
United States use ICD-10 codes for billing as required by CMS.
Therefore, we believe that ICD-based comorbid conditions can
be easily obtained electronically and hold great promise for HAI
risk adjustment.
While it is tempting to analyze all comorbid conditions for
which data are available as possible risk factors, caution must
be exercised when conducting and interpreting tests of statis-
tical association. Statistically signiﬁcant results obtained from
large datasets might not be biologically meaningful or neces-
sarily indicate causality.24–26 Others suggest the identiﬁcation
of biologically plausible causal variables to be critical.27 Thus,
the Delphi method serves a critical role of identifying causal
table 2. Descriptive Measures of and Changes Between Rounds in Expert Ratings of Perceived Causal Relatedness of Comorbid Condi-
tions with Surgical Site Infection (N= 9)
Experts’ Likert
Ratings of 3, 4,













in IQR From Round





in SD From Round
1 to Round 2?
Alcohol abuse 44 44 2 (2) 2 (1) Y 2.22 (1.09) 2.33 (0.71) Y
Anemia (blood loss) 89 100 3 (1) 3 (1) N 3.22 (0.97) 3.44 (0.53) Y
Anemia (deﬁciency) 44 33 2 (1) 2 (1) N 2.33 (0.71) 2.33 (0.50) Y
Cardiac arrhythmia 0 0 1 (0) 1 (0) N 1.22 (0.44) 1.00 (0.00) Y
Cerebrovascular disease 33 0 2 (2) 2 (0) Y 2.00 (0.87) 1.89 (0.33) Y
Chronic pulmonary disease 56 89 3 (1) 3 (0) Y 2.56 (0.53) 2.89 (0.33) Y
Coagulopathy 67 100 3 (1) 3 (1) N 3.00 (1.00) 3.44 (0.53) Y
Congestive heart failure 56 100 3 (1) 3 (1) N 2.89 (1.05) 3.33 (0.50) Y
Depression 0 0 1 (1) 1 (0) Y 1.44 (0.53) 1.22 (0.44) Y
Dementia 22 22 2 (1) 2 (0) Y 1.78 (0.83) 2.11 (0.60) Y
Diabetes 100 100 4 (1) 4 (1) N 4.22 (0.83) 4.33 (0.50) Y
Diabetes w/complication 100 100 5 (1) 5 (0) Y 4.67 (0.50) 4.89 (0.33) Y
Drug abuse 44 44 2 (2) 2 (1) Y 2.22 (1.09) 2.33 (0.71) Y
Fluid and electrolyte disorders 33 0 2 (1) 2 (0) Y 2.33 (0.50) 2.00 (0.00) Y
Hemiplegia or paraplegia 56 100 3 (1) 3 (0) Y 2.67 (1.00) 3.22 (0.44) Y
HIV/AIDS 56 78 3 (2) 3 (0) Y 3.11 (1.27) 3.00 (0.71) Y
Hypertension 0 0 1 (1) 1 (0) Y 1.44 (0.53) 1.11 (0.33) Y
Hypertension complicated 11 0 2 (1) 2 (1) N 1.78 (0.67) 1.67 (0.50) Y
Hypothyroidism 0 0 1 (1) 1 (0) Y 1.44 (0.53) 1.00 (0.00) Y
Lymphoma 100 100 3 (1) 4 (0) Y 3.56 (0.73) 4.11 (0.33) Y
Malignancy 89 100 4 (1) 4 (1) N 3.56 (0.88) 3.67 (0.50) Y
Metastatic solid tumor 100 100 4 (1) 5 (1) N 3.89 (0.78) 4.56 (0.53) Y
Myocardial infarction 0 0 2 (0) 2 (0) N 1.78 (0.44) 1.89 (0.33) Y
Mild liver disease 44 44 2 (1) 2 (1) N 2.44 (0.88) 2.56 (0.73) Y
Severe liver disease 78 100 3 (1) 3 (1) N 3.33 (1.32) 3.56 (0.73) Y
Neurologic (other) 0 0 2 (1) 1 (1) N 1.56 (0.53) 1.44 (0.53) N
Obesity 100 100 4 (1) 5 (1) N 4.44 (0.53) 4.56 (0.53) N
Peptic ulcer 0 0 1 (1) 1 (0) Y 1.33 (0.50) 1.00 (0.00) Y
Peripheral vascular disease 89 100 4 (1) 4 (0) Y 3.56 (0.73) 3.89 (0.33) Y
Psychosis 0 0 1 (1) 1 (1) N 1.33 (0.50) 1.33 (0.50) N
Pulmonary circulation disorders 44 11 2 (1) 2 (0) Y 2.44 (1.13) 2.00 (0.50) Y
Renal disease 89 100 4 (1) 3 (1) N 3.44 (0.73) 3.33 (0.50) Y
Rheumatologic disease 56 89 3 (1) 3 (0) Y 2.78 (0.83) 2.89 (0.33) Y
Valvular disease 11 0 2 (1) 1 (1) N 1.78 (0.97) 1.33 (0.50) Y
Weight loss (malnutrition) 89 100 3 (1) 4 (1) N 3.44 (0.88) 3.56 (0.53) Y
NOTE. IQR, interquartile range; SD, standard deviation; HIV/AIDS, human immunodeﬁciency virus/acquired immune deﬁciency syndrome.
aRatings were deﬁned as follows: 1, not at all related; 2, minimally related; 3, somewhat related; 4, very related; 5, strongly related.
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variables that should help guide model selection in risk factor
studies and predictive modeling for risk adjustment. For this
reason, our study is novel in using expert consensus to identify
potentially causal variables that can guide appropriate use
of results from statistical analyses of comorbid condition-
outcome (SSI or CLABSI) associations and can guide future
risk factor and risk adjustment studies. Using the Delphi
method, not only were we able to incorporate the strength of
the ratings for each variable selected by a majority, we also
improved consensus as indicated by decrease in both the IQR
and standard deviation between rounds 1 and 2.
This study was limited by a relatively small panel of experts;
however, this size has been considered appropriate for a
homogenous group.15,28 We only explored conditions that are
components of the Charlson and Elixhauser scores. However,
collectively, these scores include many important and relevant
comorbid diseases. The Chronic Disease Score,29,30 which has
shown promise in the ﬁeld of antibiotic resistance, was not
studied because of the lack of standardization in mapping
medications in most electronic medical records. This lack of
mapping makes the use of medication-based risk adjustment
much more complicated; it is not currently feasible to incor-
porate it into national reporting systems such as the CDC
NHSN system. Another limitation of our methodology is that
the Delphi method uses group discussion that prevents
anonymity of the expert panel. A limitation of our method is
that we assessed surgical site infection as a whole and not site-
speciﬁc surgical procedures, which may have distinct impor-
tant risk factors.
In summary, we have identiﬁed comorbid conditions based
on ICD classiﬁcations that can be used for future HAI risk-
factor studies and future risk-adjustment studies. Large studies
involving multiple hospitals exploring ICD-based risk-factor
analysis and risk-factor adjustment are needed. We hope that
the CDC strongly considers including ICD-based comorbid
condition risk adjustment in the near future.
ﬁgure 1. Perceived causal relatedness; comorbid conditions by percentage of expert ratings between 3 (somewhat related) to 5 (strongly
related). (A) CLABSI and (B) SSI.
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